|
Impact of premature venetoclax (Ven) discontinuation/interruption on outcomes in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Phase III MURANO study results. |
|
|
Consulting or Advisory Role - Abbvie/Genentech; Adaptive Biotechnologies; Celgene; Janssen Oncology; Loxo; PER; Pharmacyclics; Prime Oncology; Sunesis Pharmaceuticals; TG Therapeutics; Verastem; Verastem |
Research Funding - Abbvie/Genentech; Adaptive Biotechnologies; BeiGene; Genentech; LOXO; Pharmacyclics; Regeneron; Sunesis Pharmaceuticals; TG Therapeutics; Verastem |
Travel, Accommodations, Expenses - Pfizer; TG Therapeutics |
Other Relationship - Celgene; TG Therapeutics |
|
|
Consulting or Advisory Role - Abbvie; Acerta Pharma; AstraZeneca; Bayer Health; Celgene; Pharmacyclics; Roche; TG Therapeutics |
Research Funding - Abbvie; Acerta Pharma; AstraZeneca; Celgene; Pharmacyclics; TG Therapeutics |
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; Celgene |
Other Relationship - Abbvie; Pfizer |
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
No Relationships to Disclose |
|
|
|
Stock and Other Ownership Interests - Genentech |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Roche |
|
|
|
Stock and Other Ownership Interests - Roche |
Travel, Accommodations, Expenses - Roche |
|
|
Employment - Edwards Lifesciences |
Stock and Other Ownership Interests - Edwards Lifesciences |
Consulting or Advisory Role - Genentech |
|
|
Consulting or Advisory Role - Abbvie; Acerta Pharma; Celgene; Janssen; Roche; Takeda Science Foundation |
Speakers' Bureau - Abbvie; Celgene; Roche |
Research Funding - Abbvie; Celgene; Janssen; Roche |
Travel, Accommodations, Expenses - Abbvie |